US › Healthcare

Aardvark Therapeutics, Inc. Common Stock (AARD)

US · Healthcare · Biotechnology

$7.23+2.12%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-21.6M
Profit YoY
-131.9%
EPS
$-0.99
EPS estimate
$-0.80

EPS came in at -0.99 against a street estimate of -0.80 — a miss of 23.7%.

Key statistics

Market cap
$144.4M
Forward P/E
0.0
P/B
1.66
Book value
$3.99
EPS (TTM)
$-3.21
52-week high
$17.94
52-week low
$3.35
50-day MA
$5.01
200-day MA
$8.55

Analyst view

Analysts rate Aardvark Therapeutics, Inc. Common Stock a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $14.50.

Shareholding

Insiders
16.12%
Institutions
56.08%

Largest institutional holders

FundStake
Decheng Capital LLC17.90%
Citadel Advisors Llc5.68%
LAURION CAPITAL MANAGEMENT LP4.73%
BlackRock Inc3.62%
Vanguard Capital Management, LLC2.53%
Polygon Management Ltd1.45%
Geode Capital Management, LLC1.41%
Adage Capital Partners Gp LLC1.37%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Aardvark Therapeutics, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.